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KRAS mutationAbstract Background: Platinum-based chemotherapy is the most common treatment in
advanced-stage lung adenocarcinoma. Because the clinical signiﬁcance of KRAS mutational
status in this setting has not yet been clearly determined, a mutation subtype-speciﬁc analysis
was performed in the so far largest cohort of Caucasian patients with KRAS mutant
advanced-stage lung adenocarcinoma treated with platinum-based chemotherapy.
Methods: 505 Caucasian stage III–IV lung adenocarcinoma patients with known amino acid
substitution-speciﬁc KRAS mutational status and treated with platinum-based chemotherapy
were included. The correlations of subtype-speciﬁc KRAS mutations with smoking status,ustria.
1820 M. Cserepes et al. / European Journal of Cancer 50 (2014) 1819–1828progression-free and overall survival (PFS and OS, respectively) and therapeutic response
were analysed.
Results: Among 338 KRAS wild-type, 147 codon 12 mutant and 20 codon 13 mutant patients,
there were no mutation-related signiﬁcant differences in PFS or OS (P values were 0.534 and
0.917, respectively). Eastern Cooperative Oncology Group (ECOG) status and clinical stage
were signiﬁcant independent prognostic factors. KRAS mutation showed a signiﬁcant corre-
lation with smoking status (P = 0.018). Importantly, however, G12V KRAS mutant patients
were signiﬁcantly more frequent among never-smokers than all other codon 12 KRAS mutant
(G12x) subtypes (P = 0.016). Furthermore, this subgroup tended to have a higher response
rate (66% versus 47%; P = 0.077). A modestly longer median PFS was also found in the
G12V mutant cohort (233 days; versus 175 days in the G12x group; P = 0.145).
Conclusions: While KRAS mutation status per se is neither prognostic nor predictive in stage
III–IV lung adenocarcinoma, subtype-speciﬁc analysis may indeed identify clinically relevant
subgroups of patients that may ultimately inﬂuence treatment decisions.
 2014 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
KRAS is a proto-oncogene that is a central regulator
of the growth factor receptor tyrosine kinase signalling
cascades. KRAS is a pivotal downstream component
of the epidermal growth factor receptor (EGFR) signal-
ling pathway and KRAS and EGFR activating muta-
tions have been described to be usually mutually
exclusive [1,2]. Oncogenic mutations of KRAS are fre-
quently identiﬁed in colorectal and pancreatic cancers
and in lung adenocarcinoma [3]. In the latter, the muta-
tion rate was found to be up to 30% [4,5]. Monoclonal
antibodies (mABs) against EGFR as monotherapy or
in combination with chemotherapy demonstrated eﬃ-
cacy only in KRAS wild-type (WT) colorectal cancer
[6–8]. Diﬀerent anti-EGFR drugs (including mABs and
small molecule tyrosine kinase inhibitors (TKIs)) have
also been developed for the treatment of human non-
small cell lung cancer (NSCLC). A clear association
between KRAS mutations in NSCLC and eﬃcacy of
anti-EGFR mABs has not been demonstrated though
[9,10]. As a predictor of beneﬁt for anti-EGFR mABs,
EGFR immunohistochemistry seems to be the most
promising biomarker in NSCLC thus far. Speciﬁcally,
high NSCLC tissue EGFR protein levels were found
to predict beneﬁt from cetuximab [11], whereas the pre-
dictive value of KRAS mutation and EGFR FISH (ﬂuo-
rescent in situ hybridization) tests for NSCLC patients
treated with cetuximab could not be shown [12]. The
clinical value of KRAS mutation to predict therapeutic
response to EGFR–TKI treatment in NSCLC is also
ambiguous [13,14] and thus EGFR mutational status
analysis is currently the preferred test in this setting [15].
Although several groups investigated KRAS muta-
tions in NSCLC patients treated with chemotherapy,
the predictive power of KRAS mutational status as a
marker for chemosensitivity in NSCLC also remains
controversial [16,17]. A prospective study of 83 patients
with advanced lung adenocarcinoma, for example,showed no signiﬁcant diﬀerence between KRAS mutant
and WT patients in the objective response rate, progres-
sion-free survival (PFS) or overall survival (OS) when
treated with platinum-based chemotherapy [18]. A retro-
spective analysis of EGFR and KRAS mutations in
patients with locally advanced or metastatic (stage
IIIB–IV) NSCLC from the TRIBUTE (Tarceva
Responses in Conjunction with Paclitaxel and Carbo-
platin) trial showed that although KRAS mutations
were associated with signiﬁcantly decreased time to pro-
gression (TTP) and OS, there was no diﬀerence in che-
motherapy response based on KRAS mutational status
[19]. A subsequent molecular analysis [20] of the data
of the NCIC CTG JBR.10 study (which evaluated the
role of adjuvant cisplatin plus vinorelbine versus obser-
vation alone in completely resected stage IB and II
NSCLC [21]) also failed to show signiﬁcant interactions
between chemotherapy and KRAS mutations.
Recent studies in colorectal cancer found prognostic
[22] and both chemotherapy- and anti-EGFR treat-
ment-related predictive eﬀects of subtype-speciﬁc codon
12 and 13KRASmutations [23–25]. In surgically resected
NSCLC, Slebos et al. [26] and Rosell et al. [27] were
among the ﬁrst to demonstrate that KRAS mutations
were associated with an unfavourable prognosis. In
1991, Mitsudomi et al. reported that Ras mutation was
a negative prognostic factor also in advanced-stage
NSCLC, irrespective of the treatment intent [28]. Of note,
preclinical lung adenocarcinoma studies suggested that
subtype-speciﬁc KRAS codon 12 mutations have distinct
biological consequences andmay impact diﬀerentially the
sensitivity of tumour cells to speciﬁc treatment modalities
[29]. In a recent study on a cohort of (predominantly)
early-stage lung adenocarcinoma patients, Villaruz et al.
failed to demonstrate an association between subtype-
speciﬁc KRAS mutations and PFS or OS [30]. A more
recent study on the largest pooled cohort of patients with
early-stage resected NSCLC also suggested that diﬀerent
KRAS codon 12 amino acid substitutions are neither
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[31]. Interestingly, in this latter study, a potentially unfa-
vourable eﬀect of chemotherapy in KRAS codon 13
mutant cases was shown as well [31]. Nevertheless, in
advanced-stage lung adenocarcinoma the clinical signiﬁ-
cance of amino acid substitution-speciﬁc KRAS muta-
tional status in terms of tumour recurrence after
chemotherapy and OS has not yet been clearly estab-
lished. Therefore, in order to better understand the inﬂu-
ence of KRAS mutations in this setting, we analysed the
so far largest cohort of Caucasian patients with KRAS
mutant stage III-IV lung adenocarcinoma who were trea-
ted with platinum-based chemotherapy.2. Methods
2.1. Patients
In our retrospective analysis, patients with histologi-
cally veriﬁed unresectable stage III or IV lung adenocar-
cinoma were included who underwent ﬁrst-line
platinum-based (cisplatin or carboplatin) chemotherapy
at the National Koranyi Institute of Pulmonology and
at the Department of Pulmonology, Semmelweis Univer-
sity between January 2009 and May 2012. All patients
were (re)staged using the 7th edition of the TNM classiﬁ-
cation [32]. According to our inclusion criteria, all
patients were treated with a platinum-based doublet reg-
imen (unresectable stage III patients received chemother-
apy in combination with radiotherapy). 197 (39%) and
308 (61%) patients were treated with cisplatin and carbo-
platin, respectively. Platinum was most frequently given
together with paclitaxel (58%). Other partners were gem-
citabine (31%), pemetrexed (9%) and docetaxel (2%). All
patients were Caucasians. Lung cancer therapy guidelines
of the participating centres did not allow the use of cyto-
toxic chemotherapy in patients with ECOG (Eastern
Cooperative Oncology Group) performance status
(PS) > 1. Accordingly, only patients with initial ECOG
PS 0 or 1 and complete clinical follow-up were included.
Smoking status and TNM stage were evaluated at the
time of diagnosis. For the calculation of PFS andOS, date
of the ﬁrst chemotherapy was used. Clinical follow-up
was closed on the 1st of February, 2013. Informed con-
sent was obtained from all patients and the study was
done with the approval of the ethics committees of the
host institutions and in accordance with the ethical stan-
dards prescribed by the Helsinki Declaration of the
World Medical Association.2.2. KRAS mutation analysis
Based on the knowledge that KRAS, EGFR and
ALK (anaplastic lymphoma kinase) mutations are
mutually exclusive (with very rare reported exceptions)
[33], in Hungary KRAS testing is performed at ﬁrst toexclude KRAS mutant cases from EGFR analysis as
part of a diagnostic algorithm elaborated to reduce costs
and to optimise testing eﬃciency. This screening strategy
allows analysing large numbers of cases for KRAS
mutations. For the current study, all mutational analy-
ses were performed at the 2nd Department of Pathology
and at the 1st Department of Pathology and Experimen-
tal Cancer Research, Semmelweis University as previ-
ously described [34]. Brieﬂy, tumour-rich microscopic
area on H&E staining had been determined by patholo-
gists prior to macrodissection from the formalin ﬁxed
paraﬃn-embedded tissue. DNA was extracted using
the MasterPuree DNA Puriﬁcation Kit (Epicentre Bio-
technologies, WI) according to the instructions of the
manufacturer. KRAS mutations were screened by a
microﬂuid-based restriction fragment detection system
characterised by 5% mutant tumour cell content sensi-
tivity. The sense primer was a mismatch primer, and
the polymerase chain reaction (PCR) product contained
the recognition site of BstNI or BglI restriction endonu-
clease in case of the WT KRAS gene. DNA ampliﬁca-
tions were performed with AmpliTaq Gold (Applied
Biosystems Inc., CA) and primer pairs as follows:
KRAS codon 12: 50-GAATATAAACTTGTGGTAGT
TGGACCT-30 and 50-GGTCCTGCACCAGTAATA
TG-30 and codon 13: 50-GAATATAAACTTGTGGTA
GTTGGACCT-30 and 50-GGTCCTGCACCAGTAAT
ATG-30. The reaction mixture of reagents for samples
was prepared, containing 2.5 ll 10 PCR
buﬀer + Mg2+, 200 lM from each dNTP, 1.00 pM/reac-
tion of each primer, 0.8 U of AmpliTaq Gold DNA
polymerase per reaction. Both reactions went through
38 cycles of denaturation at 95 C for 1 min, primer
annealing at 55 C for 1 min and chain elongation at
72 C for 2 min. The ampliﬁed products were digested
with 80U BstNI (New England BioLabs, MA) at codon
12 and 80U BglI at codon 13. Enzymatic digestions were
performed at 60 C (codon 12) and 37 C (codon 13) for
4 h in a total volume of 30 lL. The digested PCR prod-
ucts were analysed by microﬂuid based Experion gel
electrophoresis system (Experione DNA 1 K Analysis
Kit; Bio-Rad Laboratories, CA). Density ratio of the
mutated band to the WT one was calculated and sam-
ples containing >5% of the non-WT band were consid-
ered mutation positive due to the sensitivity threshold.
The base-pair substitution in the mutant samples was
veriﬁed and determined by sequencing on the ABI
3130 Genetic Analyzer System (Life Technologies,
Carlsbad, CA) with the BigDye Terminator v1.1 Kit.2.3. Statistical methods
Categorical parameters of the patients with diﬀerent
mutational status were statistically analysed by the
Chi-square test. Kaplan–Meier survival curves and
two-sided log-rank tests were used for univariate
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proportional hazards model was used for uni- and mul-
tivariate survival analyses to detect the impact of both
continuous and categorical factors and to calculate the
hazard ratios (HR) and corresponding 95% conﬁdence
intervals (CI). For multivariate survival analyses, the
Cox regression model was adjusted for age (as a contin-
uous variable), sex (female versus male), smoking status
(never- versus ever-smoker), ECOG PS (0 versus 1) and
stage (III versus IV). In order to establish potential pre-
dictive factors, interaction terms were calculated
between mutational status and other variables (age,
sex, smoking status, ECOG PS and stage) in the
adjusted multivariate Cox regression model. P values
are always given as two-sided and were considered sta-
tistically signiﬁcant below 0.05. Metric data are always
shown as median or mean and corresponding range
or, in case of OS and PFS, as median and corresponding
95% CI. All statistical analyses were performed using the
PASW Statistics 18.0 package (Predictive Analytics
Software, SPSS Inc., Chicago, IL, USA).Table 1
Correlation of clinicopathologic features, outcome variables and KRAS m
(n = 505).
No. of patients (%) KRAS stat
WT (%)
All patients 505 (100%) 338 (67%)
Age (years)a
<55 109 (21.6%) 66 (19.5%)
55–64 251 (49.7%) 166 (49.1%
P65 145 (28.7%) 106 (31.4%
Smokingb
Never-smoker 63 (12.5%) 49 (14.5%)
Ever-smoker 398 (78.8%) 249 (73.7%
Gender
Male 262 (51.9%) 186 (55%)
Female 243 (48.1%) 152 (45%)
ECOG PS
0 279 (55.2%) 190 (56.2%
1 226 (44.8%) 148 (43.8%
Stage
III 167 (33.1%) 115 (34%)
IV 338 (66.9%) 223 (66%)
Responsec
PD + SD 240 (47.5%) 157 (46.4%
CR + PR 245 (48.5%) 161 (47.6%
Survival
Median PFS (days)d 211 (189–2
Median OS (days)d 479 (395–5
ECOG PS, Eastern Cooperative Oncology Group performance status. PD
partial response
a Mean age was 60.1 years (range, 33–79; SD = 8.04) for the entire patien
58.8 years (range, 39–78; SD = 8.16) for the KRAS codon 12 mutant gro
mutant cohort.
b In 44 cases, smoking status was not available.
c In 20 cases, response data were not available.
d Conﬁdence interval (95%) is given in parentheses; data shown in paren3. Results
3.1. KRAS mutations in advanced lung adenocarcinoma
The total number of patients with KRAS mutational
status available was 1125. Of these 764 (67.9%) cases
were identiﬁed as KRAS WT, 335 (29.8%) as KRAS
codon 12 mutant and 26 (2.3%) as KRAS codon 13
mutant. The overall mutation rate was 32.1% (361 out
of 1125). Thus 92.8% of the mutations occurred on
codon 12 and 7.2% on codon 13.3.2. Patient characteristics and KRAS codon 12 and
codon 13 mutational status
Based on our inclusion criteria (platinum-based che-
motherapy with initial surgically unresectable stage III
or IV disease and ECOG PS of 0 or 1 and complete clin-
ical follow-up), we enrolled 338 (67%) KRAS WT, 147
codon 12 mutant (29%) and 20 codon 13 mutant (4%)
patients. All patients had a Caucasian background. Inutational status in patients with advanced pulmonary adenocarcinoma
us P value
KRAS12 (%) KRAS13 (%)
147 (29%) 20 (4%)
35 (23.8%) 8 (40%) 0.119
) 77 (52.4%) 8 (40%)
) 35 (23.8%) 4 (20%)
13 (8.8%) 1 (5%) 0.059
) 132 (89.8%) 17 (85%)
66 (44.9%) 10 (50%) 0.120
81 (55.1%) 10 (50%)
) 77 (52.4%) 12 (60%) 0.307
) 70 (47.6%) 8 (40%)
47 (32%) 5 (25%) 0.668
100 (68%) 15 (75%)
) 72 (49%) 11 (55%) 0.260
) 75 (51%) 9 (45%)
32) 185 (156–214) 157 (0–323) 0.534
63) 471 (329–613) 330 (185–475) 0.917
, progressive disease; SD, stable disease; CR, complete response; PR,
t population, 60.7 years (range, 33–79; SD = 7.93) for the WT patients,
up and 58.1 years (range, 47–73; SD = 8.02) for the KRAS codon 13
theses are column percentages.
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tions, we performed comparative statistical analysis of
KRAS mutational status and clinicopathological vari-
ables (summarized in Table 1). Signiﬁcant associations
of KRAS mutational status with chemotherapy (data
not shown) or gender, response, stage, PFS or OS
(Table 1) were not detected. The presence of KRAS
mutation did not show statistically signiﬁcant correla-
tion with age when patients were grouped as <55, 55–
64 and >65 years (P = 0.119). However, one-way analy-
sis of variance (ANOVA) test with Tukey multiple com-
parison indicated a signiﬁcant diﬀerence between the
average ages of WT and KRAS codon 12 mutant
patients (60.7 versus 58.8 years, respectively;
P = 0.032). Importantly, ever-smoking and KRAS
mutational statuses showed an almost signiﬁcant posi-
tive correlation (P = 0.059, Table 1). However, when
KRAS mutant cases were combined (all KRAS WT
patients versus codon 12 plus codon 13 KRAS mutants;Fig. 1. Kaplan–Meier curves for the OS of advanced lung adenocar-
cinoma patients treated with platinum-based chemotherapy according
to (A) ECOG PS (P < 0.0001, log-rank test), (B) disease stage at
diagnosis (P < 0.0001, log-rank test) and (C) KRAS mutational status
(there was no statistically signiﬁcant information from these curves in
any comparisons (P = 0.621, log-rank test)).n = 298 versus 167 cases, respectively, Table 1), the ten-
dency towards a higher frequency of KRAS mutations
in ever-smoker patients reached a statistically signiﬁcant
level (P = 0.018; versus never-smokers; Chi-square test).
Accordingly, we found a signiﬁcantly elevated risk for
ever-smoker advanced lung adenocarcinoma patients
to carry a KRAS mutation (HR = 1.93; CI = 1.1136–
3.3512; P = 0.0089) that translates to an almost twofold
risk of having a KRAS mutant tumour.3.3. Prognostic factors in advanced lung adenocarcinoma
treated with platinum-based chemotherapy
When clinicopathological factors (ECOG PS, gender,
tumour stage, KRAS status) were tested for discriminat-
ing power in predicting disease outcome, we observed
that patients with ECOG 0 PS had signiﬁcantly better
OS than did ECOG PS 1 patients (P < 0.001, log-rank
test; Fig. 1A). We also found that patients with stage
III tumours had signiﬁcantly longer OS than did
patients with a stage IV tumour (P < 0.001, log-rank
test; Fig. 1B). However, there was no statistically signif-
icant eﬀect of KRAS mutational status of tumours on
OS (P = 0.621, log-rank test; Fig. 1C). ECOG PS and
clinical stage proved to be independent prognosticators
for both OS and PFS in a multivariate Cox regressionTable 2
Clinicopathological variables and survival of patients with advanced
pulmonary adenocarcinoma (n = 505) in the Cox proportional hazards
model.
Overall survival Progression-free survival
Age (continuous)
HR 0.987 0.979
95% CI (0.972–1.003) (0.966–0.992)
P 0.101 0.002
Gender (female versus male)
HR 1.213 1.055
95% CI (0.952–1.546) (0.861–1.294)
P 0.119 0.604
Smoking (never- versus ever-smokers)
HR 1.208 1.127
95% CI (0.864–1.688) (0.846–1.502)
P 0.269 0.413
ECOG PS (0 versus 1)
HR 1.871 1.620
95% CI (1.463–2.394) (1.310–2.005)
P <0.001 <0.001
Stage (III versus IV)
HR 1.487 1.738
95% CI (1.150–1.924) (1.397–2.162)
P 0.002 <0.001
KRAS status (WT versus mutant)
HR 1.020 0.962
95% CI (0.794–1.310) (0.780–1.186)
P 0.876 0.717
HR, hazard ratio; CI, conﬁdence interval; ECOG PS, Eastern Coop-
erative Oncology Group performance status.
Table 3
Correlation of clinicopathologic features, outcome variables and KRAS codon 12 subtypes in patients with advanced pulmonary adenocarcinoma
(n = 136 a).
G12C (n = 61) G12V (n = 29) G12D (n = 27) Rare (n = 19) P
Ageb (years)
<55 15 (24.6%) 6 (20.7%) 7 (25.9%) 4 (21.1%) 0.767
55–64 35 (57.4%) 16 (55.2%) 13 (48.1%) 8 (42.1%)
P65 11 (18%) 7 (24.1%) 7 (25.9%) 7 (36.8%)
Gender
Male 28 (45.9%) 14 (48.3%) 13 (48.1%) 5 (26.3) 0.407
Female 33 (54.1%) 15 (51.7%) 14 (51.9%) 14 (73.7%)
Smoking
Never-smoker 3 (4.9%) 6 (20.7%) 1 (3.7%) 3 (15.8%) 0.055
Ever-smoker 58 (95.1%) 23 (79.3%) 26 (96.3%) 16 (84.2%)
ECOG PS
0 28 (45.9%) 16 (55.2%) 17 (63%) 10 (52.6%) 0.507
1 33 (54.1%) 13 (44.8%) 10 (37%) 9 (47.4%)
Stage
III 19 (31.1%) 8 (27.6%) 7 (25.9%) 8 (42.1%) 0.664
IV 42 (68.9%) 21 (72.4%) 20 (74.1) 11 (57.9%)
Response
PD + SD 30 (49.2%) 10 (34.5%) 15 (55.6%) 12 (63.2%) 0.219
CR + PR 31 (50.8%) 19 (65.5%) 12 (44.4%) 7 (36.8%)
Survival
Median PFS (days)c 191 (153–229) 233 (138–328) 150 (91–209) 198 (120–276) 0.135
Median OS (days)c 561 (425–697) 470 (328–61) 325 (165–485) 559 (141–977) 0.801
ECOG PS, Eastern Cooperative Oncology Group performance status; PD, progressive disease; SD, stable disease; CR, complete response; PR,
partial response.
a In 11 KRAS codon 12 mutant cases the exact nucleotide change was not identiﬁable.
b Mean age was 58.8 years (range, 39–78; SD = 8.16) for the entire KRAS codon 12 mutant group, 58.1 years (range, 39–76; SD = 8.00) for the
G12C patients, 59.5 years (range, 41–76; SD = 8.14) for the G12V patients, 59.1 years (range, 39–75; SD = 8.28) for the G12D patients and
59.6 years (range, 40–78; SD = 8.68) for patients with rare KRAS codon 12 mutations; data shown in parentheses are column percentages.
c Conﬁdence interval (95%) is given in parentheses.
Fig. 2. Distribution of patients according to smoking status in the (A) KRAS WT, KRAS codon 12 and codon 13 groups and in the (B) KRAS
codon 12 subtypes. KRAS mutation is signiﬁcantly more frequent among former- or current- than in never-smokers (P = 0.032, Chi-square test).
G12V KRAS mutation is more frequent in never-smokers.
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age as a signiﬁcant negative prognostic factor for PFS
but not for OS (P values were 0.002 and 0.101, respec-
tively, Table 2).
3.4. Subtype-speciﬁc KRAS codon 12 mutations in
advanced lung adenocarcinoma: Clinical relevance and
association with smoking history
Next, we investigated the characteristics of patients
with KRAS mutations in codon 12 and performed a sta-tistical analysis on their association with amino acid-
speciﬁc mutational status. Similar to the overall cohort,
smoking status and speciﬁc KRAS codon 12 mutations
showed an almost signiﬁcant correlation (P = 0.055,
Table 3). Therefore, the correlation of mutational status
and smoking status was further analysed (Fig. 2). Codon
12 KRAS mutations were signiﬁcantly more frequent in
current and/or former-smokers than in never-smokers
(P = 0.032, Fig. 2A). Importantly, the amino acid-spe-
ciﬁc mutation subtype analysis identiﬁed G12V KRAS
mutation as more frequent in never-smokers than
Fig. 3. Comparison of (A) smoking history, (B) response rate and (C) PFS of lung adenocarcinoma patients with G12V versus all the other codon
12 KRAS mutations (G12x). (A) G12V is signiﬁcantly more frequent in never-smokers than other codon 12 KRAS mutant (G12x) cases
(P = 0.016, Chi-square test). (B) The subgroup of patients with G12V tumours tended to respond better to platinum-based chemotherapy (data
presented as number of patients; P = 0.077). (C) Furthermore, patients with G12V KRAS mutant tumours tended to have longer PFS than those
with other codon 12 (G12x) mutations (median PFSs were 233 versus 175 days, respectively, P = 0.145).
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Further analysing the G12V subgroup, we found that
G12V KRAS mutant patients are signiﬁcantly more fre-
quent among never-smokers than other codon 12 KRAS
mutant (G12x) cases (P = 0.016, Fig. 3A). This sub-
group of patients tended to respond better to plati-
num-based chemotherapy (P = 0.077, Fig. 3B).
Furthermore, they had a statistically not signiﬁcant
but clinically notable longer PFS: the median PFS val-
ues were 233 and 175 days in the G12V and G12x
cohorts, respectively (P = 0.145, Fig. 3C). Of note, this
diﬀerence has diminished in the OS (data not shown).
4. Discussion
The prognostic and predictive power and thus the clin-
ical utility of KRAS oncogenic mutations in lung cancer
are highly debated issues [15]. A major obstacle to draw
a deﬁnitive conclusion is the vast heterogeneity of the
studies in terms of ethnicity, histological subtype, tumour
stage and treatment modality. Therefore, in the current
study we analysed a well-deﬁned Caucasian patient
cohort with stage III–IV lung adenocarcinoma treated
with platinum-based chemotherapy within a 3-year-long
period. KRAS mutation rate in the presented cohort
(32.1%) is in line with other large NSCLC studies if case
numbers are adjusted for adenocarcinoma [16,19]. Fur-
thermore, we found a similar ratio of codon 12 and 13
mutations (92.8% and 7.2%, respectively) [19]. We used
direct sequencing to determine the amino acid-speciﬁc
subtype of the KRASmutant tumours. Of note, the prev-
alences of the major subtypes (G12C (42% and 38.6%),
G12V (20% and 18.4%), G12D (15% and 17.1%) and
G12A (7% and 5.1%)) is almost identical in the COSMIC
database [35] and in the current study, respectively.
We observed no diﬀerence in response rate or survival
beneﬁt between KRAS mutant or KRAS WT patients
treated with platinum-based chemotherapy. This ﬁnding
is in line with the results of the TRIBUTE trial that
included a similar patient cohort and all patients
received platinum-based chemotherapy [19]. Similarly,neither a prospective study of 83 NSCLC patients with
advanced adenocarcinoma [18] nor a more recent retro-
spective study of 161 NSCLC patients [36] showed sig-
niﬁcant diﬀerence between KRAS mutant and WT
cases in PFS or OS when treated with platinum-based
chemotherapy. Although authors of the JBR.10 study
found that KRAS mutant patients tended to have less
beneﬁt from adjuvant chemotherapy than did those with
KRAS WT tumours, this tendency did not reach statis-
tical signiﬁcance [20]. However, a recent pooled analysis
of four randomised trials (including the JBR.10 trial)
showed that KRAS codon 13 mutations (mutations
were found at codon 13 in 24 patients) may be a negative
predictor of survival after adjuvant chemotherapy in
resected early-stage lung adenocarcinoma when com-
pared to the observational arms of the included studies
[31]. In the current study we found no evidence of such
an interaction, however, evidently, in our advanced-
stage and platinum-based chemotherapy treated patient
cohort there were no untreated patients available to per-
form direct comparison. Of note, an investigation into
diﬀerences in the eﬀect of chemotherapy on PFS based
on KRAS codon and/or substitution types was not per-
formed in the already published studies of advanced-
stage NSCLC [37,38]. Nevertheless, it is also important
to mention that there was a statistically non-signiﬁcant
trend towards better OS in the relatively smaller subset
of patients (n = 17) with codon 13 mutations in the
study of Villaruz et al. on another largely early-stage
cohort of adenocarcinoma patients [30]. Altogether,
international collaborative studies are needed, therefore,
to allow adequate case numbers for analyses and to
ensure suﬃcient statistical power to establish the true
prognostic and predictive value of codon 13 mutations
for chemotherapy in lung adenocarcinoma.
Although it has recently been demonstrated in colo-
rectal carcinoma that G12V transversion leads to poor
therapy response and survival [39], the clinical relevance
of speciﬁc mutations in KRAS codon 12 remains to be
established in advanced lung adenocarcinoma. In the
two recent and so far largest studies of early-stage
1826 M. Cserepes et al. / European Journal of Cancer 50 (2014) 1819–1828adenocarcinoma, neither the eﬀect of chemotherapy on
PFS nor the OS of patients diﬀered among the
subpopulations with various codon 12 subtypes
[30,31]. Additionally, the two currently available studies
on advanced-stage NSCLC failed to demonstrate signif-
icant association between KRAS codon 12 subtypes and
OS [37,38]. However, the predictive value for chemo-
therapy beneﬁt among the subpopulations with diﬀerent
codon 12 subtypes was not investigated in the latter two
studies. In our cohort, patients with G12V KRAS
mutant adenocarcinomas not only tended to respond
better to platinum-based chemotherapy but, although
non-signiﬁcantly, were also more likely to have a longer
PFS than those with other codon 12 mutations. This
ﬁnding is in line with a recent in vitro study in which
Garassino et al. found strong diﬀerences in treatment
response to cisplatin among KRAS overexpressing
clones of human lung adenocarcinoma cells (NCI-
H1299) with diﬀerent amino acid substitutions [29].
Because platinum-based chemotherapy is the standard
treatment for the majority of patients with locally
advanced and advanced NSCLC, our study did not ana-
lyse untreated patients, and thus the true predictive
value of speciﬁc KRAS mutation subtypes for chemo-
therapy response cannot be conﬁrmed. Nevertheless,
the observation of Garassino et al. [29] that G12V
mutant cells responded better to cisplatin chemotherapy
(whereas the most common G12C transversion showed
the least response), taken together with our presented
results, allows us to hypothesise that lung adenocarci-
noma patients with diﬀerent subtype-speciﬁc KRAS
mutations might have distinct response patterns to plat-
inum-based chemotherapy and, furthermore, that sub-
type-speciﬁc mutation analysis may help to identify the
most eﬀective treatment regimen for each individual
patient.
In NSCLC, KRAS codon 12 is recognised as a
preferential site for cigarette smoke-induced mutagen-
esis, and thus mutations in this codon are more com-
mon in tumours of ever-smokers [40,41]. Codon 12
KRAS mutation in our cohort was also signiﬁcantly
associated with cigarette smoking. Interestingly, how-
ever, we found that never-smokers were signiﬁcantly
more likely to have a G12V transversion mutation
than other subtypes of codon 12 mutation. This
observation is not in line with previous studies
[31,37,38,40,42] where G12D appeared to be the most
frequent mutation among never-smokers compared
with other codon 12 mutation subtypes. Although
the reasons for this discrepancy between the above
studies and our cohort are unclear, the diﬀerence
might be explained by ethnic factors since we ana-
lysed patients only of Caucasian background whereas
the above studies included mixed US cohorts
[31,38,40] or patients with East-Asian [37,42] origin.
Nevertheless, our ﬁnding raises the possibility thatnot all subtypes of codon 12 mutations are associated
with smoking in Caucasian lung adenocarcinoma
patients.
Several studies have demonstrated that never-smok-
ers have improved OS. However, most likely the
increased survival is owing to the overall better perfor-
mance and the lack of smoking related co-morbidities
[43–46]. The predictive value of smoking status with
regard to standard chemotherapy, however, remains
controversial. Most studies found no predictive power
[44,47] or reported only slightly increased survival in
never-smokers treated with chemotherapy when com-
pared to smokers [48,49]. In our cohort, there was no
diﬀerence in OS or PFS between never- and ever-smok-
ers (data not shown). Nevertheless, we found that G12V
KRAS mutant cases were signiﬁcantly more frequent
among never-smokers than other codon 12 KRAS
mutant subtypes. The increased response rate and med-
ian PFS of the G12V mutant cohort might be related to
the presumably better prognosis of never-smokers.
However, obviously, further studies are needed to clarify
the complex interaction between smoking, KRAS muta-
tional status and the response to chemotherapy in
NSCLC.
Like all retrospective analyses, our study has several
limitations. First, and as discussed in the previous para-
graph, it remains unclear whether the G12V mutation
itself confers a more benign behaviour. Second, as it
was also mentioned above, our study did not include a
control group without platinum-based chemotherapy
and thus a possible prognostic role cannot be distin-
guished from a predictive value of speciﬁc KRAS muta-
tion subtypes on chemotherapy response. Finally, data
on pack-years of cigarette smoking, which may be asso-
ciated with substitution-speciﬁc KRAS mutational sta-
tus, were not available in our cohort. Thus, altogether,
to address the above limitations, additional large lung
adenocarcinoma cohorts should be analysed. The inte-
gration of next-generation sequencing into routine
molecular diagnostics will generate a massive body of
subtype-speciﬁc mutational information in future stud-
ies. This will provide the opportunity to study even lar-
ger cohorts of patients. Furthermore, in order to better
clarify the role of smoking in the prediction of the dis-
ease course of lung adenocarcinoma, the prospective
collection of pack-year data would be of importance.
In summary, because the evidence available so far
does not support the use of KRAS mutation testing
for predicting chemo- (or anti-EGFR) therapy beneﬁt
in the clinical practice of NSCLC therapy, at present it
can only be used as initial screening for EGFR and
ALK analysis due to the mutually exclusive appearance
of these oncogenic mutations. However, if subsequent
studies conﬁrm that either codon 13 mutations in an
adjuvant setting or, as the present study suggests, certain
codon 12 mutations may have predictive power for plat-
M. Cserepes et al. / European Journal of Cancer 50 (2014) 1819–1828 1827inum-based chemotherapy in advanced disease, then
subtype-speciﬁc KRAS mutation testing might become
an integral part of personalised medical treatment of
lung adenocarcinoma. Nevertheless, additional large
international collaborative studies are required to deﬁne
the precise and optimal role of KRAS mutational testing
in the NSCLC treatment paradigm.Conﬂict of interest statement
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